Prostate cancer (PCa) is one of the most common cancer in males. Previous studies indicated that MIR22HG was a tumor suppressor in various cancers. However, the expression pattern and functional roles of MIR22HG in PCa remained to be further investigated. In this study, we for the first time showed MIR22HG was down-regulated in PCa. Furthermore, we observed the lower expression levels of MIR22HG were significantly related to higher Gleason score and T stage. Of note, we found that higher MIR22HG expression was associated with better disease-free survival and overall survival time in PCa. Moreover, we constructed a MIR22HG mediated co-expression network. Bioinformatics analysis showed MIR22HG was associated with regulating inflammatory response, regulation of transcription, cellular response to tumor necrosis factor, neutrophil chemotaxis, cell-cell signaling, and TNF signaling pathway. These results showed that MIR22HG could serve as a novel biomarker for prostate cancer.

中文翻译：

---

长链非编码 RNA MIR22HG 在前列腺癌中下调。

前列腺癌 (PCa) 是男性最常见的癌症之一。先前的研究表明，MIR22HG 是各种癌症中的肿瘤抑制因子。然而，MIR22HG 在 PCa 中的表达模式和功能作用仍有待进一步研究。在这项研究中，我们首次表明 MIR22HG 在 PCa 中被下调。此外，我们观察到 MIR22HG 的较低表达水平与较高的 Gleason 评分和 T 分期显着相关。值得注意的是，我们发现较高的 MIR22HG 表达与 PCa 中更好的无病生存期和总生存期相关。此外，我们构建了一个 MIR22HG 介导的共表达网络。生物信息学分析显示 MIR22HG 与调节炎症反应、转录调节、细胞对肿瘤坏死因子的反应、中性粒细胞趋化性、细胞间信号通路和 TNF 信号通路。这些结果表明，MIR22HG 可以作为前列腺癌的新型生物标志物。